Discover Anaveon®’s Publications

Anaveon has successfully taken ANV419 through preclinical and clinical trials, and the research and development so far has been documented and shared through publications.

You can read about the science behind the therapy, its validity and the results so far in these publications.

Selected Publications

Anaveon presents clinical trial OMNIA-2

ASCO annual Meeting. 2023 Jun 2-6

Anaveon Presents Trial in Progress Data for OMNIA-1

ASCO Annual Meeting. 2023 June 2-6

Anaveon presents ANV600, a novel development compound

AACR Annual Meeting. 2023 Apr 14-19

ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein with potent CD8 T cell and NK cell stimulating capacity that shows additive efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity

ESMO Congress. 2022 Sep 9-13

ANV419, an IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, induces selective effector cell proliferation in patients with progressed cancer

AACR Annual Meeting. 2022 Apr 8-13

Favorable pre-clinical safety profile of the novel not-alpha IL-2 agonist ANV419 supports first in human clinical development

SITC Annual Meeting. 2021 Nov 10-14

ANV419 is a novel CD122 selective IL 2/anti IL 2 antibody fusion protein with potent CD8+ T cell
and NK cell stimulatory function in vitro and in vivo

SITC Annual Meeting. 2020 Nov 9-14

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2

Sci Transl Med. 2016 Nov 30;8(367):367ra166.

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms

Immunity. 2015 May 19;42(5):815-25

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11906-11

Selective stimulation of T cell subsets with antibody-cytokine immune complexes

Science. 2006 Mar 31;311(5769):1924-7